Abstract. The aim of this study was to investigate the role of microRNA (miR)-130a in the pathogenesis of myocardial hypoxia/reoxygenation (H/R) injury. Primary rat cardiomyocytes were cultured and subjected to H/R treatment. Reverse transcription-quantitative polymerase chain reaction was performed to detect the levels of miR-130a, western blot analysis was used to determine the expression of various proteins, and CCK-8 assay was performed to determine cell viability. In addition, flow cytometry was used to assess apoptosis. The cell viability was significantly decreased and the apoptosis rate was significantly increased in H/R-treated primary cardiomyocytes, and the expression level of miR-130a was also elevated in these model cells. Transfection with miR-130a inhibitor significantly elevated the cell viability and reduced the apoptosis rate in H/R-treated cardiomyocytes. Bioinformatics analysis indicated that autophagy-related gene 14 (ATG14) is the target for miR-130a, which was confirmed by dual-luciferase reporter assay and western blot analysis. When the H/R model cells were co-transfected with miR-130a inhibitor and small interfering RNA against ATG14, the cell viability was significantly reduced and the apoptosis rate was significantly elevated, compared with that of cells transfected with miR-130a inhibitor alone. miR-130a inhibitor transfection significantly elevated the levels of ATG14 and phosphorylated (p-)Beclin 1, increased the LC3II/LC3I ratio, and decreased the expression levels of P62 and cleaved caspase-3, while the co-transfection of miR-130a inhibitor and siR-ATG14 attenuated these effects in H/R-induced primary cardiomyocytes. These results indicate that miR-130a is involved in H/R-induced injuries in primary cardiomyocytes, and that the inhibition of miR-130a increases the levels of ATG14 and p-Beclin 1, thereby increasing autophagy and inhibiting apoptosis in these cells.
Introduction
Myocardial ischemia/reperfusion (I/R) injury is a common pathological process observed in the clinic. I/R injury may be regulated by various factors, including oxidative stress, Ca 2+ overload, myocardial energy metabolism disorder and cellular apoptosis (1) . The occurrence of autophagy in myocardial cells during ischemia and hypoxia has been confirmed by numerous in vivo and in vitro studies, which might either promote the survival of myocardial cells or induce cell death (2, 3) . It has been shown that the knockout of autophagy-related gene 5 (ATG5) in cardiac tissues may lead to spontaneous cardiac hypertrophy (2) .
MicroRNA (miR) is a class of non-coding RNA, which is 18-22 nucleotides in length and participates in the regulation of cell proliferation, apoptosis and differentiation (4) . In recent years, the effects of miR on the pathogenesis of heart diseases have attracted increasing attention. miR-130a has been shown to be expressed in the embryonic cardiac tissue, participating in the heart development process, and it has been suggested that upregulated miR-130a expression in embryonic cardiomyocytes might cause the ventricular muscle to be thinner and lead to abnormal heart structure (5). Moreover, miR-130a overexpression has been demonstrated to reduce the expression level of connexin 43, a major cardiac gap junction protein in mice, resulting in atrial and ventricular arrhythmias (6) . In addition, it has been shown that the expression level of miR-130a is downregulated in various I/R models (7, 8) . However, the exact role of miR-130a in the pathogenesis of I/R injury, particularly its association with autophagy, has not yet been fully elucidated.
In the present study, hypoxia/reoxygenation (H/R)-treated primary rat myocardial cells were used as an in vitro model for myocardial I/R injury, and the role of miR-130a in the pathogenesis of H/R in myocardial cells, as well as the underlying mechanisms, were investigated.
Materials and methods
Primary cell culture and identification. A total of 10 male Sprague-Dawley rats (age, 1-3 days) were provided by Shanghai Laboratory Animal Center (Shanghai, China). These rats were housed at 25˚C, under 50% humidity, feeding on normal diet. The animal experimental procedures were approved by the Ethics Committee of the Laiwu City People's Hospital (Laiwu, China). Following disinfection with 75% ethanol, the rats were sacrificed by cervical dislocation, and the ventricular muscle was removed. The tissue was cut into 1-mm 3 pieces, and digested with 0.25% trypsin in PBS buffer at 37˚C 12-18 times (5 min each time). The supernatant was collected, and Dulbecco's modified Eagle's medium (Gibco; Thermo Scientific, Inc., Waltham, MA, USA) containing 15% FBS (Gibco; Thermo Scientific, Inc.) was added to stop the digestion. The cells were harvested using centrifugation at 800 x g at room temperature for 10 min, and re-suspended in fresh culture medium. The cardiomyocytes were purified using the differential adhesion separation method (9) , and 100 µmol/l bromodeoxyuridine was used to inhibit the proliferation of other cells. After 72-h culture, these cardiomyocytes were used in the following experiments.
Cell transfection. The miR-130a mimics, miR-130a inhibitor, negative control (NC) and riboFECT™ CP transfection reagent were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The small interfering RNA (siRNA) and NC sequence for ATG14 were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The primary cardiomyocytes were first incubated with serum-free medium for 12 h, and then transfection was performed using Lipofectamine 2000 (Invitrogen; Thermo Scientific, Inc.), according to the manufacturer's instructions. Different concentrations of siRNA (25, 50 and 100 nM) were used for ATG14 inhibition and 100 nM siR-ATG14 was chosen for the following experiments. Control and H/R myocytes were transfected with NC sequences.
H/R induction. At 24 h after transfection, the cardiomyocytes were subjected to H/R induction, following previously published protocols (10, 11) . These cells were cultured with serum-free medium in a 95% N 2 plus 5% CO 2 atmosphere at 37˚C for 6 h, and then incubated with normal medium in a 95% air plus 5% CO 2 atmosphere at 37˚C for 24 h. The procedures were repeated three times.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from the cardiomyocytes with the RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA). Reverse transcription (Toyobo, Tokyo, Japan) was performed to synthesize the cDNA template, with 500 ng RNA, 4 ml 5X Mix, and ddH 2 O (to 20 ml), according to the following conditions: 37˚C for 15 min, 50˚C for 5 min, and 98˚C for 5 min. qPCR was performed using a QuantiNova SYBR Green RT-PCR kit from Qiagen. The primers for miR-130a and U6 were purchased from Guangzhou Fulengen Co., Ltd. (Guangzhou, China). The primer sequences were as follows: miR-130a, CAGUGCAAUGUUAAAAG; U6 forward, 5'-CTC GCT TCG GCA GCA CA-3' and reverse, 5'-ACG CTT CAC GAA TTT GCG T-3'; ATG14 forward, 5'-ACC AGC ATT AGC ATC ACG -3' and reverse, 5'-AGG TCC TTG GGT TGT TTT-3'; GAPDH forward, 5'-CCT CAA GAT TGT CAG CAA T-3 ' and reverse, 5'-CCA TCC ACA GTC TTC TGA GT-3'. The PCR conditions consisted of denaturation at 95˚C for 1 min; 95˚C for 15 sec, 60˚C for 30 sec and 72˚C for 15 sec, for 40 cycles; and a final extension at 72˚C for 1 min. The relative expression levels of target genes were calculated with the 2 -ΔΔCq method (12) . Negative controls were set up using ddH 2 O instead of template. Experiment was performed in triplicates.
Western blot analysis. Cardiomyocytes were collected and lysed with the RIPA lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) on ice for 15 min. Following centrifugation at 12,000 x g at 4˚C for 10 min, the protein concentration was determined using the BCA method. A 30-µg sample of protein was separated with 10% SDS-PAGE, and transferred onto a polyvinylidene difluoride membrane. The membrane was then blocked with 5% fat-free milk at room temperature for 1 h, and incubated with rabbit anti-ATG14 primary antibody (BS8969; 1:1,000; Bioworld Technology, Inc., Minneapolis, MN, USA), rabbit anti-phosphorylated-Beclin 1 primary antibody (84966; 1:1,000; Cell Signaling Technology, Inc., Beverly, CA, USA), rabbit anti-LC3 primary antibody (AL221; 1:1,000; Beyotime Institute of Biotechnology), rabbit anti-P62 primary antibody (5114), rabbit anti-cleaved caspase-3 primary antibody (9661; both 1:1,000; Cell Signaling Technology, Inc.), and mouse anti-GAPDH primary antibody (BS60630; 1:2,000; Bioworld Technology, Inc.), respectively, at 4˚C overnight. Subsequently, the membrane was incubated with goat anti-rabbit secondary antibody (BS13271) and goat anti-mouse secondary antibody (BS12471; both 1:5,000; Bioworld Technology, Inc.), respectively, at room temperature for 1 h. The blot was developed with the ECL method (Beyotime Institute of Biotechnology, Haimen, China). Protein bands were detected using Quantity One software (Bio Rad Laboratories, Inc., Hercules, CA, USA).
Cell viability assay. The viability of cardiomyocytes was assessed with the CCK-8 assay kit (Beyotime Institute of Biotechnology). The primary cells were planted onto a 96-well plate. After transfection, 10 µl CCK-8 was added and the cells were incubated in a 37˚C, 5% CO 2 atmosphere for 1 h. The absorbance at 450 nm was then read with a microplate reader (Thermo Fisher Scientific, Inc.). The cell viability was calculated according to the manufacturer's instructions.
Flow cytometry. The apoptotic process was evaluated with flow cytometry. Following digestion with 1 ml Trypsin (Gibco; Thermo Fisher Scientific, Inc., Grand Island, NY, USA) at 37˚C for 3 min and washing, the cardiomyocytes were incubated with 100 µl binding buffer, 5 µl Annexin V/fluorescein isothiocyanate and 5 µl propidium iodide in the dark at room temperature for 15 min. After 1 h, the fluorescence was detected using a flow cytometer (BD FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA) and the apoptosis rate was calculated using BD FACSuite software (BD Biosciences).
Dual-luciferase reporter assay. The potential target sequences for miR-130a in the 3'-untranslated region (3'-UTR) of ATG14 and the mutated sequences of this 3'-UTR were as follows:
Wild-type ATG14 3'-UTR, 5'-AUU UUG CAC UG-3'; and mutant ATG14 3'-UTR: 5'-AGU CUA CGC AG-3'. These sequences were amplified, and cloned into psiCHECK™ reporter plasmids (Promega Corporation, Madison, WI, USA) to obtain wt-ATG14-3'-UTR and mut-ATG14-3'-UTR plasmids. The reconstructed plasmids were co-transfected with miR-130a or NC mimics into 293T cells from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Results were obtained and analyzed according to the manufacturer's instructions. All experiments were repeated three times independently.
Bioinformatics analysis. Target genes of miR 130a were predicted using TargetScan software (www.targetscan.org).
Statistical analysis. Data were expressed as mean ± standard deviation. SPSS version 19.0 software was used for statistical analysis (IBM SPSS, Armonk, NY, USA). The t-test was used for pair-wise comparison, while analysis of variance was performed for multiple comparison. P<0.05 was considered to indicate a statistically significant difference.
Results

H/R decreases cell viability and increases apoptosis in primary
cardiomyocytes. To investigate the effects of H/R treatment on primary cardiomyocytes, cell viability and apoptosis were detected with CCK-8 assay and flow cytometry, respectively. The results from the CCK-8 assay showed that, compared with the control group, cell viability was significantly decreased in primary cardiomyocytes following H/R treatment (P<0.01; Fig. 1A) . Moreover, the results from flow cytometry showed that, compared with the control group, the apoptosis rate was significantly increased in H/R-induced primary cardiomyocytes (P<0.01; Fig. 1B) . These results indicate that the H/R treatment significantly decreased the cell viability and increased the apoptosis rate of primary cardiomyocytes.
miR-130a participates in H/R-induced injuries in primary cardiomyocytes.
The expression level of miR-130a in H/R-induced cardiomyocytes was detected with RT-qPCR. The results showed that, compared with the control group, the expression level of miR-130a was significantly elevated in primary cardiomyocytes following H/R treatment (P<0.01; To further investigate the role of miR-130a in the pathogenesis of H/R-induced injuries in primary cardiomyocytes, these cells were transfected with miR-130a inhibitor, and RT-qPCR was performed to confirm the manipulation. The results showed that, compared with the control group, transfection with miR-130a inhibitor (25, 50 and 100 nM) significantly decreased the expression levels of miR-130a in primary cardiomyocytes in a dose-dependent manner (P<0.01; Fig. 1D ). When the H/R-induced cardiomyocytes were transfected with 100 nM miR-130a inhibitor, the cell viability was significantly elevated (P<0.05; Fig. 1A ), while the apoptosis rate was significantly reduced (P<0.05; Fig. 1B and E) in these H/R model cells. These results suggest that miR-130a is involved in H/R-induced injuries in primary cardiomyocytes.
miR-130a targets ATG14 in H/R-induced primary cardiomyocytes.
Target genes of miR-130a were predicted with TargetScan software. The results indicated that miR-130 might bind to the 3'-UTR of ATG14 at 1299-1306 bp (Fig. 2A) . The dual-luciferase reporter assay was then performed to investigate the interaction between miR-130a and ATG14. The results showed that when the miR-130a mimics and the reporter plasmid containing the wild-type 3'-UTR of ATG14 were co-transfected into the 293T cells the luminescence intensity was significantly reduced by 38% (P<0.05). By contrast, in the cells co-transfected with miR-130a mimics and the luciferase reporter plasmid containing the mutant 3'-UTR of ATG14, no significant differences were observed in the luminescence intensity (P>0.05; Fig. 2B ). To further confirm this interaction, western blot analysis was performed. The results showed that, compared with the control group, transfection with miR-130a mimics clearly reduced the protein expression level of ATG14 (Fig. 2C) . These results suggest that miR-130a targets ATG14 in the 3'-UTR and inhibits the gene expression.
To investigate the involvement of ATG14 in the pathogenesis of H/R-induced injuries, the expression of ATG14 was manipulated in primary cardiomyocytes. RT-qPCR showed that, compared with the control group, transfection with siR-ATG14 (25, 50 and 100 nM, respectively) significantly decreased the mRNA expression levels of ATG14 in primary cardiomyocytes in a dose-dependent manner (P<0.01; Fig. 3A) . The H/R-induced primary cardiomyocytes were then co-transfected with miR-130a inhibitor and siR-ATG14. The results from the CCK-8 assay and flow cytometry showed that, compared with the miR-130a-treated H/R models, siR-ATG14 significantly reduced the cell viability (P<0.05; Fig. 3B ) and elevated the apoptosis rate (P<0.05; Fig. 3C and D) , in these cells. These results suggest that the knockdown of ATG14 blocked the protective effects of miR-130a inhibitor on H/R-induced primary cardiomyocytes, which confirms the involvement of ATG14 in the miR-130a-mediated H/R injuries in these cells.
miR-130a inhibition enhances autophagy in H/R-induced primary cardiomyocytes.
ATG14 plays an important role in the initiation of autophagy (13) . Therefore, the autophagic process in the H/R-induced primary cardiomyocytes was investigated in the present study. The results of western blot analysis showed that, compared with the H/R-induced model cells, the transfection with miR-130a inhibitor clearly elevated the expression levels of ATG14 and phosphorylated Beclin 1 (p-Beclin 1), increased the ratio of LC3II/LC3I, and decreased the expression levels of P62 (Fig. 4) , in the H/R-induced primary cardiomyocytes, indicating increased autophagy. In addition, miR-130a inhibitor transfection also decreased the expression levels of cleaved caspase-3 in the H/R-induced primary cardiomyocytes (Fig. 4) , further confirming that miR-103a inhibitor restrained the apoptotic process induced by H/R in these cells. However, co-transfection with miR-130a inhibitor and siR-ATG14 attenuated the changes in (Fig. 4) . These results suggest that the miR-130a inhibitor regulated the expression levels of ATG14 and increased autophagy in primary cardiomyocytes, thereby protecting these cells from the apoptosis induced by H/R treatment.
Discussion
Abnormal expression of various miRs has been reported in the pathogenesis of cardiovascular diseases. Recent studies have found that miR is involved in apoptosis and other injuries in myocardial cells caused by I/R (H/R) (14-16). Liu et al (17) have shown that miR-15b increases I/R-induced myocardial apoptosis through the mitochondrial pathway. Moreover, Wang et al (18) found that miR-494 is able to regulate antiand pro-apoptotic proteins to protect myocardial cells from the I/R-induced apoptosis. Furthermore, inhibition of miR-92a has been found to reduce the I/R-induced apoptosis and necrosis of myocardial cells (19) . In addition, Jakob et al (20) have shown that the expression of miR-130a is downregulated in endothelial outgrowth cells and CD34 + cells in patients with chronic heart failure caused by ischemic heart disease, and miR-130a overexpression increases cell activities, promotes angiogenesis, and improves cardiac function. It has also been shown that miR-130a is upregulated in the peripheral blood of patients with coronary heart disease, indicating an increased In the present study, the results showed that the expression levels of miR-130a in primary rat cardiomyocytes were elevated by H/R treatment. TargetScan analysis indicated that ATG14 is one of the targets of miR-130a. Therefore, the effects of miR-130a inhibitor and siR-ATG14 on the H/R-induced primary rat cardiomyocytes were investigated. It was found that miR-130a inhibitor transfection improved the survival and decreased the apoptosis of cardiomyocytes, which was blocked by co-transfection with siR-ATG14. The dual-luciferase reporter assay was then performed to further investigate whether ATG14 was the target gene for miR-130a. The results showed that co-transfection with miR-130a mimics and reporter plasmid containing the wild-type 3'-UTR of ATG14 resulted in a significant reduction in the luminescence intensity. However, in the cells co-transfected with miR-130a mimics and luciferase reporter plasmid containing the mutant 3'-UTR of ATG14, no significant differences in the luminescence intensity were observed. Moreover, western blot analysis showed that the expression level of ATG14 was decreased following transfection with miR-130a mimics. These results suggest that ATG14 is the target gene for miR-130a, and that inhibition of miR-130a regulated the expression level of ATG14 and increased autophagy to protect the cardiomyocytes against H/R-induced apoptosis and improve cell survival. ATG14, which is also known as Beclin 1-associated autophagy-related key regulator (Barkor), is located in the endoplasmic reticulum, isolation membrane and autophagosomes. ATG14 is able to increase the activity of Vps34 and plays an important role in the initiation of the autophagic process, and mutation of ATG14 results in attenuated autophagy (23, 24) . Fogel et al (25) have shown that ATG14 regulates the phosphorylation of Beclin 1, which is a core component of the phosphatidylinositol-3 complex and also plays an important role in the occurrence of autophagy. Consistent with this, the results of the present study showed that the increased expression of ATG14 was accompanied by the elevated expression of p-Beclin 1. LC3II and P62 are autophagic markers, and the LC3II/LC3I ratio reflects autophagic activity (26) . The results of the present study showed that following transfection with miR-130a inhibitor, the expression of LC3II was elevated while the level of cleaved caspase-3 was reduced in the primary cardiomyocytes. However, transfection with ATG14 decreased the expression levels of p-Beclin 1 and LC3II, indicating that autophagic activity was inhibited, but increased the expression of cleaved caspase-3, indicating increased apoptosis in these cells. The aforementioned results suggest that ATG14 affects the phosphorylation of Beclin 1 and regulates apoptotic and autophagic cell death in primary cardiomyocytes.
In conclusion, the results of the present study showed that the expression levels of miR-130a were elevated in H/R-treated primary rat cardiomyocytes, and this was associated with the pathogenesis of H/R-induced injury. The inhibition of miR-130a increased the expression level of ATG14 and the phosphorylation level of Beclin 1, therefore increasing autophagy and inhibiting apoptosis, in the H/R-induced primary cardiomyocytes. These findings might help to increase understanding of the roles of miR-130a and ATG14 in the pathogenesis of H/R-induced injuries.
